Fate Therapeutics Stock Probability of Future Stock Price Finishing Over 3.07

FATE Stock  USD 2.28  0.44  16.18%   
Fate Therapeutics' future price is the expected price of Fate Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Fate Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Fate Therapeutics Backtesting, Fate Therapeutics Valuation, Fate Therapeutics Correlation, Fate Therapeutics Hype Analysis, Fate Therapeutics Volatility, Fate Therapeutics History as well as Fate Therapeutics Performance.
For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.
  
The current year's Price Earnings To Growth Ratio is expected to grow to 0.06, whereas Price To Sales Ratio is forecasted to decline to 5.50. Please specify Fate Therapeutics' target price for which you would like Fate Therapeutics odds to be computed.

Fate Therapeutics Target Price Odds to finish over 3.07

The tendency of Fate Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 3.07  or more in 90 days
 2.28 90 days 3.07 
about 42.79
Based on a normal probability distribution, the odds of Fate Therapeutics to move over $ 3.07  or more in 90 days from now is about 42.79 (This Fate Therapeutics probability density function shows the probability of Fate Stock to fall within a particular range of prices over 90 days) . Probability of Fate Therapeutics price to stay between its current price of $ 2.28  and $ 3.07  at the end of the 90-day period is about 46.72 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.35 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Fate Therapeutics will likely underperform. Additionally Fate Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Fate Therapeutics Price Density   
       Price  

Predictive Modules for Fate Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Fate Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Fate Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.112.298.64
Details
Intrinsic
Valuation
LowRealHigh
0.183.529.87
Details
Naive
Forecast
LowNextHigh
0.052.448.79
Details
18 Analysts
Consensus
LowTargetHigh
6.627.288.08
Details

Fate Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Fate Therapeutics is not an exception. The market had few large corrections towards the Fate Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Fate Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Fate Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.7
β
Beta against Dow Jones2.35
σ
Overall volatility
0.55
Ir
Information ratio -0.09

Fate Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Fate Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Fate Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Fate Therapeutics generated a negative expected return over the last 90 days
Fate Therapeutics has high historical volatility and very poor performance
Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 63.53 M. Net Loss for the year was (160.93 M) with loss before overhead, payroll, taxes, and interest of (224.15 M).
Fate Therapeutics currently holds about 568.85 M in cash with (132.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Fate Therapeutics has a frail financial position based on the latest SEC disclosures
Over 98.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Fate Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Fate Stock often depends not only on the future outlook of the current and potential Fate Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Fate Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding98.4 M
Cash And Short Term Investments315.2 M

Fate Therapeutics Technical Analysis

Fate Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Fate Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Fate Therapeutics. In general, you should focus on analyzing Fate Stock price patterns and their correlations with different microeconomic environments and drivers.

Fate Therapeutics Predictive Forecast Models

Fate Therapeutics' time-series forecasting models is one of many Fate Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Fate Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Fate Therapeutics

Checking the ongoing alerts about Fate Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Fate Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Fate Therapeutics generated a negative expected return over the last 90 days
Fate Therapeutics has high historical volatility and very poor performance
Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 63.53 M. Net Loss for the year was (160.93 M) with loss before overhead, payroll, taxes, and interest of (224.15 M).
Fate Therapeutics currently holds about 568.85 M in cash with (132.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Fate Therapeutics has a frail financial position based on the latest SEC disclosures
Over 98.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.64)
Revenue Per Share
0.123
Quarterly Revenue Growth
0.581
Return On Assets
(0.22)
Return On Equity
(0.47)
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.